Prospects to translate the biology of IL-33 and ST2 during organ transplantation into therapeutics to treat graft-versus-host disease

Annals of Translational Medicine

Volumn 4, Issue 24, 2016, Pages

  Scott, Ian C ^a   Houslay, Kirsty F ^a   Cohen, E Suzanne ^a  

^a MEDIMMUNE LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CNT03914; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 33; NEUTRALIZING ANTIBODY; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 33; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BIOLOGICAL ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; EDITORIAL; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; MORTALITY; NONHUMAN; ORGAN TRANSPLANTATION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL;

EID: 85010289487     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.21037/atm.2016.11.74     Document Type: Editorial

References (25)

1. Martin NT, Martin MU. Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol 2016;17:122-31.
2. Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol 2016;16:676-89.
3. Cohen ES, Scott IC, Majithiya JB, et al. Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat Commun 2015;6:8327.
4. Lefrançais E, Cayrol C. Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members. Eur Cytokine Netw 2012;23:120-7.
5. Kearley J, Silver JS, Sanden C, et al. Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity 2015;42:566-79.
6. Kaur D, Gomez E, Doe C, et al. IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk. Allergy 2015;70:556-67.
7. Donovan C, Bourke JE, Vlahos R. Targeting the IL-33/IL-13 Axis for Respiratory Viral Infections. Trends Pharmacol Sci 2016;37:252-61.
8. Salvagno GL, Pavan C. Prognostic biomarkers in acute coronary syndrome. Ann Transl Med 2016;4:258.
9. Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 2013;369:529-39.
10. Qian L, Wu Z, Shen J. Advances in the treatment of acute graft-versus-host disease. J Cell Mol Med 2013;17:966-75.
11. Zhang J, Ramadan AM, Griesenauer B, et al. ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Sci Transl Med 2015;7:308ra160.
12. Reichenbach DK, Schwarze V, Matta BM, et al. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood 2015;125:3183-92.
13. Matta BM, Reichenbach DK, Zhang X, et al. Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. Blood 2016;128:427-39.
14. Turnquist HR, Zhao Z, Rosborough BR, et al. IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol 2011;187:4598-610.
15. Palmer G, Lipsky BP, Smithgall MD, et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 2008;42:358-64.
16. Schiering C, Krausgruber T, Chomka A, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 2014;513:564-8.
17. Fursov N, Johnston E, Duffy K, et al. Generation and characterization of rat anti-mouse ST2L monoclonal antibodies. Hybridoma (Larchmt) 2011;30:153-62.
18. Percival-Alwyn JL, England E, Kemp B, et al. Generation of potent mouse monoclonal antibodies to self-proteins using T-cell epitope "tags". MAbs 2015;7:129-37.
19. Liu X, Li M, Wu Y, et al. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun 2009;386:181-5.
20. Lipsky BP, Toy DY, Swart DA, et al. Deletion of the ST2 proximal promoter disrupts fibroblast-specific expression but does not reduce the amount of soluble ST2 in circulation. Eur J Immunol 2012;42:1863-9.
21. Liu X, Hammel M, He Y, et al. Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci U S A 2013;110:14918-23.
22. Ramaprakash H, Shibata T, Duffy KE, et al. Targeting ST2L potentiates CpG-mediated therapeutic effects in a chronic fungal asthma model. Am J Pathol 2011;179:104-15.
23. Mehraj V, Ponte R, Routy JP. The Dynamic Role of the IL-33/ST2 Axis in Chronic Viral-infections: Alarming and Adjuvanting the Immune Response. EBioMedicine 2016;9:37-44.
24. Guabiraba R, Besnard AG, Menezes GB, et al. IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice. Mucosal Immunol 2014;7:1079-93.
25. Byrne SN, Beaugie C, O'Sullivan C, et al. The immune-modulating cytokine and endogenous Alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation. Am J Pathol 2011;179:211-22.